Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1858 participants.
Also called NCT02814409
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,858 participants
- Sponsor
- Registry
-
NCT02814409
-
- Other papers using this trial's data
- Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02814409. Randomized; no masking; primary purpose treatment. Start 2016-12-15 (actual); primary completion 2023-08-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis
- Acronym
- ATTEST2
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
- Intervention (Drug)
- Intravenous Tenecteplase
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Collaborator
- University of Glasgow
- Collaborator
- University of Edinburgh
- Collaborator
- Oxford University Hospitals NHS Trust
Record details
- Record id
cardio:ct-nct02814409- Content hash
42154b17797701ef4a1b090435a34752f6c7144fbaffad757ef9de4799456ec2